Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
MaxCyte ( (MXCT) ) has shared an update.
MaxCyte has announced a change in its shareholder voting rights as BlackRock, Inc. adjusted its holdings, crossing a regulatory threshold. This adjustment, involving both direct and indirect voting rights, reflects BlackRock’s continued interest in MaxCyte, potentially impacting the company’s governance and stakeholder dynamics.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell engineering technology. The company provides tools and services for cell-based research and therapy development, catering to pharmaceutical and biotech companies engaged in developing advanced therapies.
YTD Price Performance: -1.84%
Average Trading Volume: 46,403
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £351.1M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.
